BellRing Brands Q3 Earnings: Sales Beat, But Margin Pressure and Lowered EBITDA Outlook Weigh
BRBR sits 38% above its 52-week low of $7.82.
Summary
BellRing Brands posted Q3 sales of $570.4M (+4% YoY) but saw Adjusted EBITDA drop 35% to $78.3M on inventory charges and cost inflation. FY2026 Adjusted EBITDA guidance was lowered to $275-$295M.
Key Events · Earnings and Guidance · BRBR
-
Q3 Sales Beat, Profit Miss
Net sales of $570.4M (+4% YoY) exceeded expectations, but Adjusted EBITDA of $78.3M missed significantly, down 35% from $120.3M a year ago.
-
Margin Compression from Inventory Charges
Gross margin fell to 28.6% from 35.4% due to a $10M excess bottle inventory charge and higher input costs, including tariffs and freight.
-
FY2026 Guidance Lowered
Adjusted EBITDA outlook cut to $275-$295M (from prior ~$300M+), now including $28M in full-year inventory-related impacts.
-
Share Repurchases Continue
BellRing bought back 4.9M shares for $133.1M at an average price of $27.41 per share; $506.9M remains under authorization.
Analysis · BRBR · Manufacturing
BellRing Brands reported Q3 FY2026 net sales of $570.4 million, a 4% increase year-over-year, driven by strong Premier Protein RTD shake consumption and Dymatize growth. However, profitability took a hit: gross margin contracted to 28.6% from 35.4% a year ago due to a $10 million excess inventory charge and persistent input cost inflation. Adjusted EBITDA fell 35% to $78.3 million. Management updated its full-year outlook, trimming the top end of Adjusted EBITDA guidance to $295 million from prior expectations, now including $28 million in inventory-related impacts. The company also repurchased 4.9 million shares for $133.1 million during the nine-month period. While demand trends remain healthy, the combination of margin compression and a lowered profit forecast signals near-term earnings pressure, making this a notable update for investors.
At the time of this filing, BRBR was trading at $10.80 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.82 to $54.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.